{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T04:34:14Z","timestamp":1789533254662,"version":"build-2803163510"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,11]],"date-time":"2025-03-11T00:00:00Z","timestamp":1741651200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,3,11]],"date-time":"2025-03-11T00:00:00Z","timestamp":1741651200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82002176"],"award-info":[{"award-number":["82002176"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017950","name":"Shanghai Municipal Health Commission","doi-asserted-by":"publisher","award":["20214Y0392"],"award-info":[{"award-number":["20214Y0392"]}],"id":[{"id":"10.13039\/100017950","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pharmacol Toxicol"],"DOI":"10.1186\/s40360-025-00894-3","type":"journal-article","created":{"date-parts":[[2025,3,11]],"date-time":"2025-03-11T19:43:46Z","timestamp":1741722226000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Post-market safety profile of cefiderocol: a real-world pharmacovigilance exploratory analysis based on U.S. FDA adverse event reporting system (FAERS)"],"prefix":"10.1186","volume":"26","author":[{"given":"Hao","family":"Lin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingmin","family":"Bi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jindong","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohan","family":"Ju","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,11]]},"reference":[{"key":"894_CR1","unstructured":"https:\/\/www.who.int\/medicines\/publications\/global-priority-list-antibiotic"},{"issue":"7","key":"894_CR2","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1093\/cid\/ciab757","volume":"74","author":"S Ong\u2019uti","year":"2022","unstructured":"Ong\u2019uti S, Czech M, Robilotti E, et al. Cefiderocol: a new cephalosporin stratagem against multidrug-resistant Gram-negative bacteria[J]. Clin Infect Dis. 2022;74(7):1303\u201312.","journal-title":"Clin Infect Dis"},{"issue":"7","key":"894_CR3","doi-asserted-by":"publisher","first-page":"796","DOI":"10.7150\/ijms.6048","volume":"10","author":"T Sakaeda","year":"2013","unstructured":"Sakaeda T, Tamon A, Kadoyama K, et al. Data mining of the public version of the FDA adverse event reporting System[J]. Int J Med Sci. 2013;10(7):796.","journal-title":"Int J Med Sci"},{"issue":"8","key":"894_CR4","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1002\/pds.1001","volume":"13","author":"KJ Rothman","year":"2004","unstructured":"Rothman KJ, Lanes S, Sacks ST. The reporting odds ratio and its advantages over the proportional reporting ratio[J]. Pharmacoepidemiol Drug Saf. 2004;13(8):519\u201323.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"6","key":"894_CR5","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1002\/pds.677","volume":"10","author":"SJW Evans","year":"2001","unstructured":"Evans SJW, Waller PC, Davis S. Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports[J]. Pharmacoepidemiol Drug Saf. 2001;10(6):483\u20136.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"894_CR6","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s002280050466","volume":"54","author":"A Bate","year":"1998","unstructured":"Bate A, Lindquist M, Edwards IR, et al. A bayesian neural network method for adverse drug reaction signal generation[J]. Eur J Clin Pharmacol. 1998;54:315\u201321.","journal-title":"Eur J Clin Pharmacol"},{"key":"894_CR7","doi-asserted-by":"crossref","unstructured":"DuMouchel W. Bayesian data mining in large frequency tables, with an application to the FDA spontaneous reporting system[J]. Am Stat. 1999;53(3):177-90.","DOI":"10.1080\/00031305.1999.10474456"},{"issue":"12","key":"894_CR8","doi-asserted-by":"publisher","first-page":"7396","DOI":"10.1128\/AAC.01405-16","volume":"60","author":"A Ito","year":"2016","unstructured":"Ito A, Nishikawa T, Matsumoto S, et al. Siderophore cephalosporin Cefiderocol utilizes ferric iron transporter systems for antibacterial activity against Pseudomonas aeruginosa[J]. Antimicrob Agents Chemother. 2016;60(12):7396\u2013401.","journal-title":"Antimicrob Agents Chemother"},{"issue":"12","key":"894_CR9","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1016\/S1473-3099(18)30554-1","volume":"18","author":"S Portsmouth","year":"2018","unstructured":"Portsmouth S, van Veenhuyzen D, Echols R, et al. Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, Randonmised, double-blind, non-inferiority trial[J]. Lancet Infect Dis. 2018;18(12):1319\u201328.","journal-title":"Lancet Infect Dis"},{"key":"894_CR10","doi-asserted-by":"crossref","unstructured":"Tamma PD, Aitken SL, Bonomo RA, et al. Infectious Diseases Society of America 2022 guidance on the treatment of extended-spectrum \u03b2-lactamase producing Enterobacterales (ESBL-E), carbapenem-resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with difficult-to-treat resistance (DTR-P. aeruginosa). Clin Infect Dis. 2022;75(2):187\u2013212.","DOI":"10.1093\/cid\/ciac268"},{"issue":"2","key":"894_CR11","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/S1473-3099(20)30796-9","volume":"21","author":"M Bassetti","year":"2021","unstructured":"Bassetti M, Echols R, Matsunaga Y, et al. Efficacy and safety of Cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial[J]. Lancet Infect Dis. 2021;21(2):226\u201340.","journal-title":"Lancet Infect Dis"},{"issue":"2","key":"894_CR12","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/S1473-3099(20)30731-3","volume":"21","author":"RG Wunderink","year":"2021","unstructured":"Wunderink RG, Matsunaga Y, Ariyasu M, et al. Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial[J]. Lancet Infect Dis. 2021;21(2):213\u201325.","journal-title":"Lancet Infect Dis"},{"key":"894_CR13","doi-asserted-by":"publisher","unstructured":"Kawai A, McElheny CL, Iovleva A, et al. Structural basis of reduced susceptibility to ceftazidime-avibactam and Cefiderocol in Enterobacter cloacae due to AmpC R2 loop deletion[J]. Antimicrob Agents Chemother. 2020;64(7). https:\/\/doi.org\/10.1128\/aac00198-20.","DOI":"10.1128\/aac00198-20"},{"issue":"3","key":"894_CR14","doi-asserted-by":"publisher","first-page":"e02670","DOI":"10.1128\/spectrum.02670-21","volume":"10","author":"Q Wang","year":"2022","unstructured":"Wang Q, Jin L, Sun S, et al. Occurrence of high levels of Cefiderocol resistance in carbapenem-resistant Escherichia coli before its approval in China: a report from China CRE-network[J]. Microbiol Spectr. 2022;10(3):e02670\u201321.","journal-title":"Microbiol Spectr"},{"key":"894_CR15","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1016\/j.jgar.2020.07.009","volume":"22","author":"N Kohira","year":"2020","unstructured":"Kohira N, Hackel MA, Ishioka Y, et al. Reduced susceptibility mechanism to cefiderocol, a siderophore cephalosporin, among clinical isolates from a global surveillance programme (SIDERO-WT-2014) [J]. J Global Antimicrob Resist. 2020;22:738\u201341.","journal-title":"J Global Antimicrob Resist"},{"issue":"6\u20137","key":"894_CR16","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1080\/00365521.2017.1291719","volume":"52","author":"ES Bj\u00f6rnsson","year":"2017","unstructured":"Bj\u00f6rnsson ES. Drug-induced liver injury due to antibiotics[J]. Scand J Gastroenterol. 2017;52(6\u20137):617\u201323.","journal-title":"Scand J Gastroenterol"},{"issue":"12","key":"894_CR17","doi-asserted-by":"publisher","first-page":"e246571","DOI":"10.1136\/bcr-2021-246571","volume":"14","author":"T Shah","year":"2021","unstructured":"Shah T, Joslyn JA, Lai J. Ceftazidime induced liver injury[J]. BMJ Case Rep CP. 2021;14(12):e246571.","journal-title":"BMJ Case Rep CP"},{"key":"894_CR18","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.ijid.2021.06.035","volume":"109","author":"K Cipko","year":"2021","unstructured":"Cipko K, Gordon AK, Adhikari S, et al. Cefiderocol treatment of Pseudomonas aeruginosa and extensively drug-resistant Acinetobacter baumannii retained spinal hardware infection causing reversible acute interstitial nephritis: Recto: Cefiderocol causing acute interstitial nephritis[J]. Int J Infect Dis. 2021;109:108\u201311.","journal-title":"Int J Infect Dis"},{"issue":"8","key":"894_CR19","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1007\/s40264-023-01316-1","volume":"46","author":"AS Garnier","year":"2023","unstructured":"Garnier AS, Drablier G, Briet M, et al. Nephrotoxicity of amoxicillin and third-generation cephalosporins: an updated review[J]. Drug Saf. 2023;46(8):715\u201324.","journal-title":"Drug Saf"},{"issue":"11","key":"894_CR20","doi-asserted-by":"publisher","first-page":"2211","DOI":"10.1016\/j.ekir.2023.08.031","volume":"8","author":"RE Campbell","year":"2023","unstructured":"Campbell RE, Chen CH, Edelstein CL. Overview of antibiotic-induced nephrotoxicity[J]. Kidney Int Rep. 2023;8(11):2211\u201325.","journal-title":"Kidney Int Rep"},{"key":"894_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12882-015-0004-x","volume":"16","author":"K Mac","year":"2015","unstructured":"Mac K, Chavada R, Paull S, et al. Cefepime induced acute interstitial nephritis\u2013a case report[J]. BMC Nephrol. 2015;16:1\u20136.","journal-title":"BMC Nephrol"},{"key":"894_CR22","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1007\/s40264-017-0578-2","volume":"40","author":"S Deshayes","year":"2017","unstructured":"Deshayes S, Coquerel A, Verdon R. Neurological adverse effects attributable to \u03b2-lactam antibiotics: a literature review[J]. Drug Saf. 2017;40:1171\u201398.","journal-title":"Drug Saf"},{"key":"894_CR23","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.jns.2019.01.018","volume":"398","author":"C Lacroix","year":"2019","unstructured":"Lacroix C, Kheloufi F, Montastruc F, et al. Serious central nervous system side effects of cephalosporins: a National analysis of serious reports registered in the French pharmacovigilance Database[J]. J Neurol Sci. 2019;398:196\u2013201.","journal-title":"J Neurol Sci"},{"issue":"6","key":"894_CR24","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.1093\/jac\/dkac066","volume":"77","author":"D Luque-Paz","year":"2022","unstructured":"Luque-Paz D, Bennis Y, Jaubert P, et al. Cerebrospinal fluid concentrations of Cefiderocol during the treatment of extensively drug-resistant Pseudomonas aeruginosa ventriculitis[J]. J Antimicrob Chemother. 2022;77(6):1787\u20139.","journal-title":"J Antimicrob Chemother"},{"issue":"1","key":"894_CR25","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1002\/phar.4632","volume":"45","author":"NA Finch","year":"2025","unstructured":"Finch NA, Granillo A, Pouya N, et al. Pharmacokinetics of Cefiderocol in a patient with carbapenem-resistant Acinetobacter baumannii ventriculitis: A case report[J]. Pharmacotherapy: J Hum Pharmacol Drug Therapy. 2025;45(1):66\u20139.","journal-title":"Pharmacotherapy: J Hum Pharmacol Drug Therapy"},{"key":"894_CR26","doi-asserted-by":"crossref","unstructured":"Marcelo C, de Gea Grela A, Palazuelos MM, et al. Clinical cure of a difficult-to-treat resistant Pseudomonas aeruginosa ventriculitis using cefiderocol: a case report and literature review. Open Forum Infectious Diseases. Oxford University Press. 2022;9(8):ofac391.","DOI":"10.1093\/ofid\/ofac391"},{"issue":"1","key":"894_CR27","doi-asserted-by":"publisher","first-page":"58","DOI":"10.3390\/antibiotics13010058","volume":"13","author":"R Nau","year":"2024","unstructured":"Nau R, Seele J, Eiffert H. New antibiotics for the treatment of nosocomial central nervous system infections[J]. Antibiotics. 2024;13(1):58.","journal-title":"Antibiotics"},{"key":"894_CR28","doi-asserted-by":"crossref","unstructured":"Lewis TC, Arnouk S. Dark red urine in a patient on Cefiderocol and ferric Gluconate[J]. Ann Pharmacother. 2022; 56(9).","DOI":"10.1177\/10600280211070029"},{"issue":"2","key":"894_CR29","first-page":"265","volume":"31","author":"T Lupia","year":"2023","unstructured":"Lupia T, Salvador E, Corcione S, et al. Dark brown urine in a patient treated with Cefiderocol[J]. Le Infezioni in Medicina. 2023;31(2):265.","journal-title":"Le Infezioni in Medicina"},{"issue":"12","key":"894_CR30","doi-asserted-by":"publisher","first-page":"e258207","DOI":"10.1136\/bcr-2023-258207","volume":"16","author":"M Smith","year":"2023","unstructured":"Smith M, Foong KS. Cefiderocol-associated brown chromaturia[J]. BMJ Case Rep CP. 2023;16(12):e258207.","journal-title":"BMJ Case Rep CP"}],"container-title":["BMC Pharmacology and Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40360-025-00894-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40360-025-00894-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40360-025-00894-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T07:30:01Z","timestamp":1741764601000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpharmacoltoxicol.biomedcentral.com\/articles\/10.1186\/s40360-025-00894-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,11]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["894"],"URL":"https:\/\/doi.org\/10.1186\/s40360-025-00894-3","relation":{},"ISSN":["2050-6511"],"issn-type":[{"value":"2050-6511","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,11]]},"assertion":[{"value":"17 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The requirement for obtaining individual patient consent was waived as the study did not have an impact on clinical care and all protected health information was de-identified.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"58"}}